GlassScriptPhysician profile
Deanna E Wallace
NPI 1861631004
$16,650.66
in general payments reported to CMS, 2019-2025
38 companies · $4,314 in 2025
The $4,314 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,340 · 2022: $2,930 · 2023: $3,333 · 2024: $3,734 · 2025: $4,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $8.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,373.12 |
| Education | $8.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,885.41 | 2021-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $2,231.77 | 2021-2025 | |
| Ucb, INC. | $1,877.82 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $1,540.32 | 2021-2025 | Saphnelo, Evusheld |
| Pfizer INC. | $1,456.31 | 2021-2025 | |
| Janssen Biotech, INC. | $1,371.53 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $805.74 | 2021-2025 | Taltz |
| Genzyme Corporation | $499.35 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $489.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $408.37 | 2021-2025 | Benlysta, Nucala |
| Organon LLC | $374.31 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Fresenius Kabi USA, LLC | $282.10 | 2023-2025 | Idacio |
| Aurinia Pharma U.S., INC. | $181.73 | 2021-2024 | Lupkynis |
| Octapharma USA, INC. | $163.26 | 2021-2023 | Octagam Immune Globulin (Human), Panzyga |
| Genentech USA, INC. | $141.81 | 2021-2025 | Actemra, Gazyva |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.